These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19663652)

  • 41. Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells.
    Irwin N; McKinney JM; Bailey CJ; McClenaghan NH; Flatt PR
    Horm Metab Res; 2011 Apr; 43(4):244-9. PubMed ID: 21165811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.
    Shin SJ; Kim JY; Kwon SY; Mun KC; Cho CH; Ha E
    Eur J Pharmacol; 2014 Nov; 743():17-23. PubMed ID: 25240713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and antidiabetic activity of morpholinothiazolyl-2,4-thiazolidindione derivatives.
    Ezer M; Yıldırım LT; Bayro O; Verspohl EJ; Dundar OB
    J Enzyme Inhib Med Chem; 2012 Jun; 27(3):419-27. PubMed ID: 21740103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Raloxifene-driven benzothiophene derivatives: Discovery, structural refinement, and biological evaluation as potent PPARγ modulators based on drug repurposing.
    Liu Q; Ma L; Chen F; Zhang S; Huang Z; Zheng X; Chen Z; Ye J; Hou N; Yi W; Zhou Z
    Eur J Med Chem; 2024 Apr; 269():116325. PubMed ID: 38527378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-edged sword against type 1 diabetes.
    Lehuen A
    N Engl J Med; 2015 Feb; 372(8):778-80. PubMed ID: 25693020
    [No Abstract]   [Full Text] [Related]  

  • 46. Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes.
    Artuso R; Provenzano A; Mazzinghi B; Giunti L; Palazzo V; Andreucci E; Blasetti A; Chiuri RM; Gianiorio FE; Mandich P; Monami M; Mannucci E; Giglio S
    Pharmacogenomics J; 2015 Feb; 15(1):49-54. PubMed ID: 25048417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.
    Eldor R; DeFronzo RA; Abdul-Ghani M
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S162-74. PubMed ID: 23882042
    [No Abstract]   [Full Text] [Related]  

  • 48. Gluten-free diet in subjects at risk for type 1 diabetes: a tool for delaying progression to clinical disease?
    Bosi E; Pastore MR; Molteni L; Bazzigaluppi E; Bonifacio E; Piemonti L
    Adv Exp Med Biol; 2005; 569():157-8. PubMed ID: 16137121
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.
    Shao H; Li D; Yang Y; Guo HF; Liu ZY; Si SY; Yang Z; Li ZR
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):282-9. PubMed ID: 19663652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
    Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
    Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
    Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
    Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.